{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T12:42:40Z","timestamp":1792154560313,"version":"4.4.0"},"reference-count":25,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2021.23930","type":"journal-article","created":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T15:42:06Z","timestamp":1630683726000},"page":"e2123930","source":"Crossref","is-referenced-by-count":34,"title":["Safety and Tolerability of Transdermal Cannabidiol Gel in Children With Developmental and Epileptic Encephalopathies"],"prefix":"10.1001","volume":"4","author":[{"given":"Ingrid E.","family":"Scheffer","sequence":"first","affiliation":[{"name":"University of Melbourne, Austin Health and Royal Children\u2019s Hospital, Florey Institute, Melbourne, Victoria, Australia"},{"name":"Murdoch Children\u2019s Research Institutes, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe","family":"Hulihan","sequence":"additional","affiliation":[{"name":"Consultant, Newtown, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Messenheimer","sequence":"additional","affiliation":[{"name":"Consultant, Moncure, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shayma","family":"Ali","sequence":"additional","affiliation":[{"name":"Department of Paediatrics and Child Health, University of Otago, Wellington, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ngaire","family":"Keenan","sequence":"additional","affiliation":[{"name":"Department of Paediatrics and Child Health, University of Otago, Wellington, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jim","family":"Griesser","sequence":"additional","affiliation":[{"name":"The Griesser Group, Conshohocken, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna L.","family":"Gutterman","sequence":"additional","affiliation":[{"name":"Zynerba Pharmaceuticals Inc, Devon, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terri","family":"Sebree","sequence":"additional","affiliation":[{"name":"Zynerba Pharmaceuticals Inc, Devon, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynette G.","family":"Sadleir","sequence":"additional","affiliation":[{"name":"Department of Paediatrics and Child Health, University of Otago, Wellington, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2021,9,3]]},"reference":[{"issue":"6","key":"zoi210698r1","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1111\/epi.2018.59.issue-6","article-title":"A population-based cost-effectiveness study of early genetic testing in severe epilepsies of infancy.","volume":"59","author":"Howell","year":"2018","journal-title":"Epilepsia"},{"issue":"8","key":"zoi210698r2","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1093\/brain\/awz195","article-title":"Incidence and phenotypes of childhood-onset genetic epilepsies: a prospective population-based national cohort.","volume":"142","author":"Symonds","year":"2019","journal-title":"Brain"},{"issue":"6","key":"zoi210698r3","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1046\/j.1528-1157.2001.10401.x","article-title":"A proposed diagnostic scheme for people with epileptic seizures and with epilepsy: report of the ILAE Task Force on Classification and Terminology.","volume":"42","author":"Engel","year":"2001","journal-title":"Epilepsia"},{"issue":"4","key":"zoi210698r4","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1111\/epi.2010.51.issue-4","article-title":"Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005-2009.","volume":"51","author":"Berg","year":"2010","journal-title":"Epilepsia"},{"issue":"9","key":"zoi210698r5","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1111\/epi.2006.47.issue-9","article-title":"Report of the ILAE classification core group.","volume":"47","author":"Engel","year":"2006","journal-title":"Epilepsia"},{"key":"zoi210698r6","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1111\/epi.2006.47.issue-s2","article-title":"Cognitive and behavioral outcomes of epileptic syndromes: implications for education and clinical practice.","volume":"47","author":"Besag","year":"2006","journal-title":"Epilepsia"},{"key":"zoi210698r7","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.pediatrneurol.2017.06.008","article-title":"Parental perception of comorbidities in children with Dravet syndrome.","volume":"76","author":"Knupp","year":"2017","journal-title":"Pediatr Neurol"},{"issue":"8","key":"zoi210698r8","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/nrneurol.2016.98","article-title":"Cognitive and neurodevelopmental comorbidities in paediatric epilepsy.","volume":"12","author":"Nickels","year":"2016","journal-title":"Nat Rev Neurol"},{"issue":"7","key":"zoi210698r9","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1001\/archneurol.2011.3275","article-title":"Progressive gait deterioration in adolescents with Dravet syndrome.","volume":"69","author":"Rodda","year":"2012","journal-title":"Arch Neurol"},{"issue":"8","key":"zoi210698r10","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1212\/WNL.0000000000003635","article-title":"Dysarthria and broader motor speech deficits in Dravet syndrome.","volume":"88","author":"Turner","year":"2017","journal-title":"Neurology"},{"key":"zoi210698r11","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.yebeh.2017.06.031","article-title":"Dravet syndrome: characteristics, comorbidities, and caregiver concerns.","volume":"74","author":"Villas","year":"2017","journal-title":"Epilepsy Behav"},{"issue":"1","key":"zoi210698r12","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/dmcn.13598","article-title":"Prevalence and risk factors for autism spectrum disorder in epilepsy: a systematic review and meta-analysis.","volume":"60","author":"Strasser","year":"2018","journal-title":"Dev Med Child Neurol"},{"issue":"4","key":"zoi210698r13","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1111\/epi.2017.58.issue-4","article-title":"ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology.","volume":"58","author":"Scheffer","year":"2017","journal-title":"Epilepsia"},{"issue":"4","key":"zoi210698r14","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s13311-015-0377-3","article-title":"Molecular targets of cannabidiol in neurological disorders.","volume":"12","author":"Ibeas Bih","year":"2015","journal-title":"Neurotherapeutics"},{"issue":"3","key":"zoi210698r15","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/S1474-4422(15)00379-8","article-title":"Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial.","volume":"15","author":"Devinsky","year":"2016","journal-title":"Lancet Neurol"},{"issue":"21","key":"zoi210698r16","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1056\/NEJMoa1611618","article-title":"Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome.","volume":"376","author":"Devinsky","year":"2017","journal-title":"N Engl J Med"},{"issue":"14","key":"zoi210698r17","doi-asserted-by":"publisher","first-page":"e1204","DOI":"10.1212\/WNL.0000000000005254","article-title":"Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome.","volume":"90","author":"Devinsky","year":"2018","journal-title":"Neurology"},{"issue":"20","key":"zoi210698r18","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1056\/NEJMoa1714631","article-title":"Effect of cannabidiol on drop seizures in the Lennox-Gastaut syndrome.","volume":"378","author":"Devinsky","year":"2018","journal-title":"N Engl J Med"},{"issue":"10125","key":"zoi210698r19","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/S0140-6736(18)30136-3","article-title":"Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial.","volume":"391","author":"Thiele","year":"2018","journal-title":"Lancet"},{"issue":"9","key":"zoi210698r20","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.3109\/03639041003657295","article-title":"Cannabidiol bioavailability after nasal and transdermal application: effect of permeation enhancers.","volume":"36","author":"Paudel","year":"2010","journal-title":"Drug Dev Ind Pharm"},{"issue":"20","key":"zoi210698r21","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"issue":"1","key":"zoi210698r22","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s11689-019-9277-x","article-title":"A phase 1\/2, open-label assessment of the safety, tolerability, and efficacy of transdermal cannabidiol (ZYN002) for the treatment of pediatric fragile X syndrome.","volume":"11","author":"Heussler","year":"2019","journal-title":"J Neurodev Disord"},{"issue":"1","key":"zoi210698r24","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.yebeh.2006.10.010","article-title":"The development and validation of the Epilepsy and Learning Disabilities Quality of Life (ELDQOL) scale.","volume":"10","author":"Buck","year":"2007","journal-title":"Epilepsy Behav"},{"issue":"4","key":"zoi210698r25","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1111\/jsr.1996.5.issue-4","article-title":"The Sleep Disturbance Scale for Children (SDSC): construction and validation of an instrument to evaluate sleep disturbances in childhood and adolescence.","volume":"5","author":"Bruni","year":"1996","journal-title":"J Sleep Res"},{"key":"zoi210698r23","unstructured":"Amtmann? D, Jensen? MP, Salem? R, . University of Washington Caregiver Stress Scale\u2014Users Guide, Version 2.0. Updated May 13, 2020. Accessed October 1, 2020. https:\/\/uwcorr.washington.edu\/wp-content\/uploads\/2020\/06\/uw-css-user-guide-v2.pdf"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2783716\/scheffer_2021_oi_210698_1630074114.34395.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T15:42:11Z","timestamp":1630683731000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2783716"}},"subtitle":["A Nonrandomized Controlled Trial"],"short-title":[],"issued":{"date-parts":[[2021,9,3]]},"references-count":25,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.23930","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,3]]}}}